Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
41
resultados
Última actualización
04/10/2026 [06:46:00]
Resumen de: KR20260136354A
본 발명은 바닐릭산 유도체 화합물에 관한 것으로서, 바닐릭산과 카테콜아민 간의 탈수축합반응에 의해 형성될 수 있다. 본 발명에 따른 바닐릭산 유도체 화합물은 알츠하이머병 및 신경염증 치료제제로 사용할 수 있다는 점에 특징이 있다. 또한 본 발명은 상기 화합물을 포함하는 알츠하이머 치료제 조성물 및 신경염증 치료제 조성물에 관한 것이다.
Resumen de: KR20260135747A
본 발명은 HCN1 채널의 CNBD 도메인에 특이적으로 결합하는 세계 최초의 소분자 개방제(ind_5F_3pyr, 5-플루오로-1H-인다졸-3-일-피리딘-3-일)에 관한 것이다. 알츠하이머병에서 HCN1 채널 발현이 감소하여 신경 흥분성 이상이 발생하며, 기존 HCN 약물은 모두 차단제로서 이를 해결할 수 없다. 본 발명의 화합물은 HCN1 CNBD에 cAMP보다 강하게 결합하고(ΔG = -8.08 vs -7.51 kcal/mol), 열린 상태를 안정화하며(apo ΔG = -8.32), 혈액뇌장벽을 투과하고(MW 213, TPSA 57), TRIP8b 대체를 통한 뇌 선택성을 달성한다. 119개 후보 중 가상 스크리닝과 분자동역학으로 동정되었다. JPEGpat00001.jpg5157
Resumen de: US20260263386A1
The present invention pertains to the anti-inflammatory therapeutic effect of xantohumol in spinal cord injury (SCI). The continuous administration of xanthohumol for 1-8 weeks to SCI rats resulted in improved results in 4 clinical tests used and in lowering and faster elimination of macrophages from the SCI lesion. Since the infiltration of the SCI lesion by numerous phagocytic macrophages indicates a severe destructive inflammation of extraordinary longevity, administration of xanthohumol is neuroprotective and resulted in a better and faster recovery of the locomotor function and the strength and sensory function in the hind limbs, in a shorter period of paralysis of the urinary bladder and in the recovery of the body weight lost due to the SCI surgery. Since the traumatic brain injury (TBI) involving the white matter, and stroke involving the white matter initiate the severe destructive inflammation as in the SCI, the administration of xanthohumol is expected to be anti-inflammatory and neuroprotective in both brain diseases. Since neurodegenerative diseases including Alzheimer's disease, frontotemporal dementia and Parkinson's disease, immune mediated neuroinflammation including multiple sclerosis and neuromyelitis optica and cerebrospinal infections have inflammatory pathogenesis involving microgliosis and infiltration by macrophages, the administration of xanthohumol is expected to result in therapeutic inhibition of progression of all above diseases as well as of rela
Resumen de: WO2026187186A1
The present invention relates to a vanillic acid derivative compound that can be formed by a dehydration condensation reaction between vanillic acid and catecholamine. The vanillic acid derivative compound according to the present invention can be used as a therapeutic agent for Alzheimer's disease and neuroinflammation. In addition, the present invention relates to a therapeutic agent composition for Alzheimer's disease and a therapeutic agent composition for neuroinflammation, each comprising the compound.
Resumen de: US20260265261A1
Compounds of Formula I:and pharmaceutically acceptable salts thereof are provided for as inhibitors of SGK-1 for example for the treatment of conditions such as Long QT syndrome, heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, stent failure, prostate cancer, epilepsy, colorectal cancer, breast cancer, Parkinson's disease and Lafora disease.
Resumen de: WO2026184543A1
Provided are a magnetogenetic system based on a clMagR gene and a use thereof in Parkinson's disease. The clMagR gene is injected into neurons by means of an adeno-associated virus (AAV) vector, and on the basis of exogenous iron and magnetic field stimulation technology, a biological function of cells or tissues is regulated. Compared with optogenetics, the system avoids optical fiber implantation and direct light source irradiation required for optogenetics by means of precise control of an external magnetic field, reduces the risk of invasive surgery, and can more widely regulate cell functions in deep neural regions in the body, especially in deep brain regions. Compared with traditional treatment methods, the present invention provides a non-invasive and regulatable gene therapy strategy, providing a new technical paradigm for fields such as stem cell therapy, nerve regeneration, drug delivery, and elucidation of the neural circuit mechanism of diseases.
Resumen de: AU2025231257A1
The present invention relates to peptides for treatment of cognitive diseases, in particular Alzeheimer's Disease, mild cognitive impairment due to Alzheimer's disease, and mild dementia due to Alzheimer's disease.
Resumen de: AU2025232421A1
Described herein, in part, are methods useful for preventing and/or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as Parkinson's disease, psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.
Resumen de: US20260263373A1
Nanoparticle compositions and methods inhibiting amyloid beta (Aβ) fibrilization in a subject in need thereof using nanoparticles to target fibril β-amyloid (fAβ)-specific scavenger receptors. Also provided is a method of using nanoparticle compositions to treat Alzheimer's disease (AD) and similar amyloidopathies.
Resumen de: AU2025234423A1
Provided are compositions for delivery of zinc finger fusion proteins that inhibit expression of tau in the nervous system using the blood-brain barrier penetrant AAV capsid proteins comprising SEQ ID. NO: 1235, and methods of using the compositions to treat neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia, and other tauopathies.
Resumen de: WO2026185478A1
The present invention relates to compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and or abnormality associated with Tau protein aggregates, including, but not limited to, Alzheimer's disease (AD). The present invention also relates to, pharmaceutical compositions comprising said compounds, methods using said compounds, combinations comprising said compounds, medicaments containing them, and their uses in diseases, disorders and/or abnormalities associated with Tau protein aggregates.
Resumen de: WO2026185857A1
A method for preventing and/or treating a disease or disorder selected from the group consisting of neurodegenerative disease, hepatic or renal disease, pulmonary disease, cardiovascular disease, cerebrovascular disease, metabolic disease, diabetes mellitus, substance use disorder (SUD), solid tumor, and any combination thereof, by administering a therapeutically effective amount of at least one anti-protozoal compound, e.g., anti-malarial and/or anti-toxoplasma compound, potentially targeting Plasmodium and/or Toxoplasma gondii. The composition may include atovaquone, proguanil, or a combination thereof with possible adjunctive therapies. Further provided are methods and kits for diagnosing Alzheimer's disease or determining an increased risk of developing Alzheimer's disease in a subject.
Resumen de: WO2026187868A1
The present disclosure provides specific anti-ac-tauK174, anti-ac-tauK274, and ac-tauK353 antibodies, or antigen-binding fragments thereof, and methods of their use in diagnosing, differentiating, targeting, staging, prognosing, and/or treating Alzheimer's Disease and related tauopathies, including traumatic brain injury. Methods of identifying a subject having early Alzheimer's Disease and related tauopathies are also provided, the methods comprising detecting proteins using at least one anti-ac-tauK174 antibody, at least one anti-ac-tauK274 antibody, and/or at least one anti-ac-tauK353 antibody. In some embodiments, the subject is ApoE4-positive.
Resumen de: WO2026187862A1
Disclosed herein are compounds of the formula: (I), as well as pharmaceutical compositions thereof, wherein the variables are defined herein. In some aspects, the compounds and compositions provided herein may be used to treat neurodegenerative disorders, such as Alzheimer's disease. Also provided are methods of administering compounds and compositions provided herein to a patient in need thereof.
Resumen de: WO2026188223A1
The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for detecting and treating early-stage Alzheimer's disease as well as other inflammatory neurologic conditions such as Huntington's Disease.
Resumen de: WO2026188235A1
The present disclosure relates to methods of preventing and/or treating neuroinflammation in a subject in need thereof. The present disclosure also relates to methods and systems for modeling aging related neurodegenerative diseases (e.g., Amyotrophic lateral sclerosis (ALS)) in vitro. The methods comprise administering one or more Angiotensin II Receptor I Blocker (ARB) to the subject. The present disclosure also relates to methods and systems for modeling aging related neurodegenerative diseases (e.g., ALS) in vitro.
Resumen de: US20260263525A1
A cell culture protocol for obtaining neural progenitor cells from induced pluripotent stem cells is described. Also described are a pharmaceutical composition and a medicament containing the neural progenitor stem cells for use in the treatment of neuro degenerative disorders such as Parkinson's disease as described.
Resumen de: WO2026185106A1
The present invention relates to the use of a pharmaceutical combination comprising molecules that rebilance the pathway of the epigenetic modulators LiN28, EZH2 and Let-7 and increases the expression of GFAP protein in particular in the treatment of all the diseases of the central nervous system (CNS) wherein LiN28, EZH2 and Let-7 dysregulation influence the expression of GFAP gene, selected from Huntington's disease, Amyotrophic Lateral Sclerosis (ALS), Schizophrenia, Bipolar Disorder, Fetal alcohol spectrum disorder and Autism. The invention further relates to the use of a pharmaceutical composition comprising said combination and at least one pharmaceutical acceptable excipient in the treatment and/or prevention of neurodegenerative diseases and neurodevelopment diseases.
Resumen de: WO2026183787A1
Provided is a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof for use in the treatment of amyotrophic lateral sclerosis represented by the following Formula (I). Also provided is a pharmaceutical composition comprising the above compound or a pharmaceutically acceptable salt, hydrate or solvate thereof for use in the treatment of amyotrophic lateral sclerosis.
Resumen de: US20260263349A1
A delayed timed release pharmaceutical composition, a preparation method therefor, and use thereof. The pharmaceutical composition comprises a tablet core. The tablet core comprises a drug-containing layer and a boosting layer stacked on the drug-containing layer. The drug-containing layer comprises a drug active ingredient. The drug active ingredient is levodopa or a derivative thereof, or a mixture of levodopa or a derivative thereof and a DOPA decarboxylase inhibitor, and accounts for 5-72.5 wt % of the content of the drug-containing layer. The pharmaceutical composition is a capsule-shaped tablet, can realize the effects of 1-3 h delayed release of the drug active ingredient and reaching a peak concentration at 6-10 h, can be used for reducing morning stiffness in patients with Parkinson's disease, and has good application prospects.
Resumen de: WO2026179739A1
Disclosed in the present invention are an aminothiazole compound and use thereof as a brain-permeable histamine H2 receptor agonist, which belong to the field of medicine. The aminothiazole compound provided in the present invention has a general structural formula represented by formula (I) and comprises a pharmaceutically acceptable salt. The aminothiazole compound of the present invention has histamine H2 receptor agonist activity and excellent blood-brain barrier permeability. Therefore, the aminothiazole compound can be used in the preparation of a medicament for treating schizophrenia, mania, attention deficit hyperactivity disorder, binge eating disorder or bulimia nervosa, autism, Parkinson's disease, ischemic brain injury, and other diseases.
Resumen de: US20260256755A1
Disclosed are novel strategies for the treatment of patients with Parkinson's disease and other primary and secondary Parkinsonian disorders by enhancing cell engraftment. Cell viability, engraftment, proliferation, migration, or differentiation of administered DA neuronal cells is enhanced by treating the patient with an antilipemic agent and/or a CSF-1R antagonist before, during and/or after transplantation of DA neuronal cells.
Resumen de: WO2026183555A1
Methods of treating a neurodegenerative disease in a subject in need thereof are provided. Exemplary methods include providing a biological sample from the subject; measuring an NfL530 peptide concentration in the biological sample; measuring at least one of an NfL284 peptide concentration and an NfL101 peptide concentration in the biological sample; determining at least one of an NfL530/NfL284 ratio and an NfL530/NfL101 ratio; and treating the subject based on the determined NfL530/NfL284 and/or NfL530/NfL101 ratio. In some embodiments, the biological sample is selected from whole blood, plasma, and cerebrospinal fluid. In some embodiments, the subject is determined to have ALS based on the determined NfL530/NfL284 and/or NfL530/NfL101 ratio.
Resumen de: WO2026183116A2
The present disclosure provides, among other things, methods for restoring neuronal cell function in a subject having a brain-related disorder and methods for improving one or more brain functions in a subject with Alzheimer's Disease (AD) or a subject that has suffered from an acute central nervous system (CNS) injury. Such methods can comprise administering to the subject one or more peptide inhibitors of Ca2+/calmodulin-dependent protein kinase II (CaMKII). The present disclosure also provides a composition comprising one or more peptide inhibitors of Ca2+/Calmodulin-Dependent Protein Kinase II (CaMKII inhibitor peptides).
Nº publicación: US20260256865A1 03/09/2026
Solicitante:
DONGGUK UNIV WISE CAMPUS INDUSTRY ACADEMY COOPERATION FOUNDATION [KR]
DONGGUK UNIV INDUSTRY ACADEMY COOPERATION FOUNDATION [KR]
DONGGUK UNIVERSITY WISE CAMPUS INDUSTRY-ACADEMY COOPERATION FOUNDATION
DONGGUK UNIVERSITY INDUSTRY-ACADEMY COOPERATION FOUNDATION
Resumen de: US20260256865A1
The present invention relates to a pharmaceutical composition for preventing or treating Alzheimer's disease, comprising, as an active ingredient, a mulberry fruit extract fermented with lactic acid bacteria. The mulberry fruit extract fermented with lactic acid bacteria improves memory and cognitive function, and thus can exhibit excellent effects on preventing, alleviating or treating Alzheimer's disease.
BOPI
Sede Electrónica
